Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer ...

A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses current efforts in increasing biosimilar adoption and pharmacy benefit manager (PBM) reform.

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of patients with neuromuscular conditions who have rare diseases at the 2025 ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing ...

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those with prior biologic use, positioning it as a potential first-line ...

Elizabeth Grush, MBA, speaks to the support, benefits, and holistic considerations that patient-centered care can provide for the betterment of patient experiences and outcomes.

Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for ...

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

An expert discusses how the VISIBLE study examined comorbidity burden in moderate to severe psoriasis across all skin tones, addressing disparities in research. It aimed to highlight unmet needs and ...